Phentermine News and Research

RSS

Phentermine is a drug that decreases your appetite.

Long-term use of inexpensive weight-loss drug may be safe and effective

An inexpensive weight-loss drug approved 60 years ago for only short-term use also may be safe and effective for longer-term treatment, according to a study conducted by researchers at Wake Forest Baptist Health and the Patient Outcomes Research to Advance Learning network.

22 Mar 2019

Study highlights factors that can reduce food cravings

Food craving, the intense desire to eat certain foods, can sabotage efforts to maintain healthy eating habits and body weight, no matter the time of year.

12 Dec 2018

Study: Higher dose of anti-seizure drug during pregnancy may increase baby's risk of cleft lip, palate

Taking a higher dose of topiramate during the first three months of pregnancy may increase a baby's risk of cleft lip or cleft palate more than when taking a lower dose, according to a study published in the December 27, 2017, online issue of Neurology, the medical journal of the American Academy of Neurology.

28 Dec 2017

New report shows how to manage patients with obesity by prescribing optimal medications

While diet, exercise and behavior modification are essential components of obesity management, a successful long-term weight loss strategy should also include avoiding or minimizing medication-related weight gain, according to a new report from Weill Cornell Medicine.

14 Feb 2017

Very few patients use FDA-approved medications for weight loss, new study suggests

Despite guidelines that advocate the use of weight loss medications to treat obesity, and the availability of FDA approved medications, very few patients use this treatment option, a new study suggests. The results will be presented Sunday, April 3, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.

5 Apr 2016

MGH investigators report that medication could augment benefits of bariatric surgery

New findings about the mechanisms involved - or not involved - in the effects of the most common form of bariatric surgery suggest that combining surgery with a specific type of medication could augment the benefits of the procedure. In a report that has been published online in the journal Endocrinology, Massachusetts General Hospital investigators report that the effects of Roux-en-Y gastric bypass (RYGB) do not utilize neurologic pathways controlled by the serotonin 2C receptor.

9 Jul 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Endocrine Society issues guideline on prescribing drugs to manage obesity, promote weight loss

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on strategies for prescribing drugs to manage obesity and promote weight loss.

16 Jan 2015

FDA approves two drugs for long-term weight loss

Options are limited in America's battle of the bulge. While diet and exercise can help in the short term, they are frustratingly ineffective in the long run.

12 Feb 2014

TSRI scientists discover viable strategy for weight loss in people

Scientists at The Scripps Research Institute have discovered key details of a brain-to-body signaling circuit that enables roundworms to lose weight independently of food intake. The weight-loss circuit is activated by combined signals from the worm versions of the neurotransmitters serotonin and adrenaline, and there are reasons to suspect that it exists in a similar form in humans and other mammals.

11 Oct 2013

Study supports topiramate as promising medication to treat addiction

The drug topiramate, typically used to treat epilepsy and more recently weight loss, may also help people addicted to both cocaine and alcohol use less cocaine, particularly heavy users, researchers in the department of Psychiatry at Penn Medicine report in a new study published in Drug and Alcohol Dependence.

19 Jul 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Study projects potential impact of FDA-approved anti-obesity medications on Medicare spending

VIVUS, Inc. announced today that a new study demonstrates that effective medical treatment providing 10% to 15% weight loss could lead to significant improvements in Medicare spending by reversing or reducing significant health consequences such as type 2 diabetes, hypertension and dyslipidemia in obese or overweight patients.

25 Mar 2013

ScinoPharm to offer commercial manufacturing of topiramate API for VIVUS' Qsymia

ScinoPharm announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of topiramate active pharmaceutical ingredient ("API") for VIVUS' Qsymia, a new drug for the treatment of obesity approved by the United States Food and Drug Administration on July 17, 2012.

19 Jul 2012

Vivus receives FDA approval for Qsymia to manage chronic weight

The U.S. Food and Drug Administration today approved Qsymia (phentermine and topiramate extended-release) as an addition to a reduced-calorie diet and exercise for chronic weight management.

18 Jul 2012

Two-drug combo increases diabetes patients’ goal achievement

Post-hoc analysis of randomized trial results shows that treating individuals with Type 2 diabetes with a combination of phentermine and topiramate increases their achievement of goals recommended for the management of their condition.

10 Jul 2012

Experimental medication helps overweight patients with diabetes shed pounds

An experimental drug helped significantly more overweight patients with diabetes shed pounds, compared with placebo, a new study finds. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Weight loss pill Qnexa wins panel vote and awaits approval

The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.

5 Apr 2012

FDA panel votes in favor of earlier rejected anti-obesity drug Qnexa

Qnexa took a step closer to approval on Wednesday, when outside advisers to the U.S. Food and Drug Administration voted 20-to-2 in favor of approval. The panel also recommended the company conduct a study to scrutinize even more closely any risk of heart problems. That study may be required after the drug is approved. Should the FDA ask for further data on heart risks before any approval, it would delay Qnexa's launch further.

26 Feb 2012

FDA EMDAC recommends approval of VIVUS' Qnexa for obesity

VIVUS, Inc. today announced that the U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee recommended Qnexa be granted marketing approval by the FDA for the treatment of obesity in adults.

23 Feb 2012